AZN · story · 3 November
AstraZeneca · 4 headlines from 4 outlets, on 3 November 2026.
Delhi High Court stayed the NPPA's ₹151 crore recovery from AstraZeneca Pharma India.
The story's tone is the average of its headlines' own scores. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Average tone of each outlet's headlines in this story, −10 to +10. Impact = headlines × strength of tone.
The Economic Times is the largest at 3.3, ahead of scanx.trade (3.3).
Source: MarketFrame news analysis
| outlet | Average tone |
|---|---|
| The Economic Times | 3.3 |
| scanx.trade | 3.3 |
| Business Upturn | 3.3 |
| InvestyWise | 3.3 |
| Outlet | Headlines | Average tone |
|---|---|---|
| The Economic Times | 1 | +3.3 |
| scanx.trade | 1 | +3.3 |
| Business Upturn | 1 | +3.3 |
| InvestyWise | 1 | +3.3 |
One or two headlines is not a lean: read these as how this story was told, not as a verdict on the outlet.
| Tone | What the article reported, and why it scored that way |
|---|---|
| +3.3 | Court blocks pricing authority action against India subsidiary, a modest relief. |
| +3.3 | Court halts recovery demand against Indian unit. |
| +3.3 | Indian unit gets temporary relief in pricing dispute. |
| +3.3 | Indian unit shielded temporarily from pricing demand. |
A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.